Insmed (NASDAQ:INSM) Price Target Increased to $74.00 by Analysts at JPMorgan Chase & Co.
Insmed (NASDAQ:INSM – Free Report) had its price target boosted by JPMorgan Chase & Co. from $72.00 to $74.00 in a research report sent to investors on Thursday, Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock. INSM has been the topic of a number of other research reports. StockNews.com […]
7 Oct 06:56 · The Markets Daily